Systemic Therapy for Elderly Patients with Gastrointestinal Cancer
Open Access
- 1 January 2011
- journal article
- review article
- Published by SAGE Publications in Clinical Medicine Insights: Oncology
- Vol. 5, CMO.S6983-99
- https://doi.org/10.4137/cmo.s6983
Abstract
The majority of patients with gastrointestinal cancers are over the age of 65. This age group comprises the minority of the patients enrolled in clinical trials, and it is unknown whether older patients achieve similar results as younger patients in terms of survival benefit and tolerability. In addition, there are few studies specifically designed for patients over 65 years. Subset analyses of individual trials and studies using pooled patient data from multiple trials provide some understanding on outcomes in older patients with gastrointestinal cancers. This article reviews the evidence on chemotherapeutic regimens in the elderly with colorectal, pancreatic, and gastroesophageal cancers, and discusses a practical approach to provide the best outcomes for older patients.Keywords
This publication has 68 references indexed in Scilit:
- Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancerJournal of Geriatric Oncology, 2013
- FOLFOX4 in the treatment of metastatic colorectal cancer in elderly patients: A prospective studyArchives of Gerontology and Geriatrics, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Adjuvant Chemotherapy Use and Adverse Events Among Older Patients With Stage III Colon CancerJAMA, 2010
- Geriatric Oncology: An Overview of Progresses and ChallengesCancer Research and Treatment, 2010
- Colorectal cancer incidence in the United States, 1999‐2004Cancer, 2009
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III StudyJournal of Clinical Oncology, 2008
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trialThe Lancet Oncology, 2008
- Capecitabine and Oxaliplatin for Advanced Esophagogastric CancerThe New England Journal of Medicine, 2008
- Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study GroupJournal of Clinical Oncology, 2006